8-K: Roivant Announces Positive Phase 3 Results for Batoclimab in Myasthenia Gravis and Phase 2b Results in Chronic Inflammatory Demyelinating Polyneuropathy

Roivant reports positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from its Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating significant clinical improvements.

Summary

• Roivant Sciences Ltd. has announced positive results from Immunovant's Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy (CIDP).
• In the MG study, batoclimab met the primary endpoint, showing a 5.6 point improvement in MG-ADL score at Week 12 with the 680mg dose and a 4.7 point improvement with the 340mg dose in AChR+ participants.
• The CIDP study demonstrated a mean improvement of 1.8 points in the adjusted INCAT disability score across batoclimab arms in Period 1.
• An 84% responder rate was observed in CIDP patients who achieved an IgG lowering greater than 70%.
• Immunovant plans to initiate pivotal studies in both MG and CIDP with IMVT-1402, having received IND clearance for both indications.
• The company will host a conference call and webcast on March 19, 2025, to discuss these updates.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for future success and improved patient outcomes. The sentiment is high due to the achievement of primary endpoints and plans for further development.

Positives

• The Phase 3 MG study showed statistically significant and clinically meaningful improvements in MG-ADL scores.
• The Phase 2b CIDP study demonstrated promising initial results with improvements in aINCAT scores and responder rates.
• Deeper IgG reductions correlated with better clinical outcomes in both studies.
• Immunovant has IND clearance for IMVT-1402 in both MG and CIDP, paving the way for pivotal studies.
• The 680mg dose of batoclimab in the MG study set a new benchmark for magnitude of benefit.
• The safety and tolerability profiles were consistent with prior batoclimab studies.

Negatives

• The placebo group in the MG study showed a 3.6 point improvement in MG-ADL, which is higher than in earlier generation FcRn studies, potentially reducing the observed treatment effect.
• The Phase 2b CIDP study is ongoing, and the primary endpoint at the end of Period 2 is not yet available.

Risks

• The development and commercialization of IMVT-1402 and batoclimab are subject to regulatory approvals and clinical trial outcomes.
• Global factors, geopolitical tensions, and adverse macroeconomic conditions could impact Immunovant's business operations and supply chain.
• Immunovant will require additional capital to fund its operations and advance its product candidates.
• Initial results may not be predictive of final trial results.
• Future clinical trials may not confirm the safety, potency, or other product characteristics described.

Future Outlook

Immunovant plans to initiate potentially registrational studies in both MG and CIDP with IMVT-1402 and is focused on leveraging data and learnings from the batoclimab studies to inform and accelerate its programs with IMVT-1402.

Management Comments

• Pete Salzmann, M.D., chief executive officer of Immunovant, stated that deeper IgG reduction leads to deeper responses in MG and CIDP.
• Pete Salzmann believes that the core thesis of deeper IgG reduction will apply to a wide range of auto-antibody mediated conditions.

Industry Context

The announcement highlights the competitive landscape of FcRn inhibitors for autoimmune diseases, with Immunovant aiming to deliver deeper and more durable responses compared to currently approved therapies. The company believes that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical outcomes.

Comparison to Industry Standards

• The 680mg dose of batoclimab demonstrated the best-in-class MG-ADL response rate, raising the ceiling of therapeutic effect observed with any FcRn.
• Batoclimab 680mg outperforms other FcRns in achieving deep response rates in MG patients across Phase 3 programs.
• Batoclimab treated patients achieved a best-in-class mean change from baseline in aINCAT score at Week 12 compared to Vyvgart Hytrulo in CIDP patients.
• The results are compared to Vyvgart (efgartigimod) and nipocalimab data from their respective Phase 3 trials in MG, noting differences in trial designs and participant characteristics.

Stakeholder Impact

• The positive results could lead to improved treatment options for patients with MG and CIDP.
• The development of IMVT-1402 could provide a best-in-class treatment option for autoimmune diseases.
• The company's progress could positively impact shareholders through increased value and potential revenue.

Next Steps

• Immunovant plans to initiate potentially registrational studies in both MG and CIDP with IMVT-1402.
• The company will wait to make a final decision about regulatory submissions for batoclimab until the results of the ongoing Phase 3 studies of batoclimab in thyroid eye disease are available.

Key Dates